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Abstract
We examined 18 neuroblastoma cell lines and 32 pri-
mary single-copy MYCN tumor specimens to determine
whether mutations of p73, a novel p53-related gene
located in chromosome band 1p36.33, contribute to the
genesis or progression of childhood neuroblastoma. By
fluorescence in situ hybridization, 16 of the 18 cell
lines, but only 3 of the 32 primary tumors, had evidence
of a deleted p73 allele. Sequence analysis of the p73
coding region in the mRNAs expressed by these cell
lines and tumors did not reveal inactivating mutations,
suggesting that p73 is not homozygously inactivated in
neuroblastoma. However, several novel splice forms of
p73 mRNAs were identified, including one without exon
11 that predominated in multiple MYCN-amplified cell
lines. Its encoded p73 protein differed from other splice
forms in that the C-terminus was derived from an alter-
native reading frame. Further study of the functional
properties of the protein encoded by this splice form of
p73 will be needed to determine whether it contributes
to the pathogenesis of childhood neuroblastoma with
MYCN gene amplification.
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Introduction
Neuroblastoma, a childhood tumor arising in the adrenal
medulla and sympathetic nervous system, is the most com-
mon extracranial solid tumor in infants and young children.
The most frequent genetic abnormality identified in neurob-
[ ]lastoma is MYCN gene amplification 1 , which has been
[ ]shown by Brodeur, Seeger, and colleagues 2,3 to have
clinical relevance, an observation since confirmed by many
[ ]others 4–8 . MYCN gene amplification is found more often
in cases with disseminated disease, is strongly associated
with rapid tumor progression, and confers a poor prognosis,
regardless of tumor stage.
Deletion of one allele of the distal short arm of chromo-
some 1 is a second clinically relevant genetic abnormality in
neuroblastoma, suggesting that inactivation of one or more
tumor suppressor genes in this region also contributes to
oncogenesis during sympathetic nervous system develop-
[ ] [ ]ment 9–13 . Studies by Caron et al. 14 have implicated at
least two tumor suppressor loci on chromosomal bands
1p35-36 in this tumor. In their study, single-copy MYCN
tumors with polymorphic markers from distal 1p36.2-3
(showed preferential loss of the maternal allele 16 of 17
)tumors analyzed . These findings suggest that a tumor
( )suppressor gene referred to here as NB1 is imprinted and
inactivated when inherited from the father, so that deletion
of the maternal allele alone results in complete loss of NB1
expression in the tumor. A second more proximal region of
( )loss of heterozygosity LOH is associated with MYCN am-
plification and a random pattern of loss of parental alleles,
( )suggesting that a separate gene referred to as NB2 is
located in the 1p35-36.1 region but is not affected by im-
[ ]printing 14,15 .
A new gene, designated p73, was recently identified and
[ ]mapped to 1p36.3 16 , the region postulated to harbor NB1
in neuroblastoma. The predicted p73 protein shares signifi-
cant amino acid sequence identity with the DNA-binding,
transactivation, and oligomerization domains of p53, provid-
ing further support for its candidacy as a tumor suppressor
gene. Like p53, p73 can activate transcription of the
p21Waf1/Cip1 cell-cycle inhibitor and can also induce apopto-
sis, although expression of p73 is not induced by
DNA-damaging agents, such as ultraviolet light or low-dose
[ ]actinomycin D 16,17 .
Initial studies have not revealed inactivating mutations in
the coding regions of the p73 gene in a small number of
both neuroblastoma and non-neuroblastoma cell lines or in
[ ]human lung cancers 16,18 . However, preliminary indica-
tions that p73 is monoallelically expressed in neuroblas-
[ ]toma and normal human blood cells 16 , together with its
distal location on chromosome arm 1p, suggest that it may
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be the imprinted NB1 tumor suppressor gene of single-copy
[ ]MYCN neuroblastomas 19,20 . These tumor cells generally
do not grow well in vitro, and thus are under-represented
among the neuroblastoma cell lines analyzed to date for
inactivating mutations of p73. In addition, if one allele was
inactivated by imprinting, only one allele would need to be
inactivated in somatic neural precursors. Thus, it is impor-
tant to look for inactivating mutations of p73 mRNA in
primary neuroblastoma tumors lacking MYCN amplification
or 1p deletion.
To test this hypothesis, we analyzed the p73 gene copy
( )number by fluorescence in situ hybridization FISH and the
mRNA sequence by reverse transcription-polymerase chain
( )reaction RT-PCR in 32 primary neuroblastoma tumors
lacking MYCN amplification. We also analyzed 18 neurob-
lastoma cell lines with and without MYCN amplification for
both p73 deletions and inactivating mutations. Our analysis
confirmed deletion of one allele of p73 in the context of 1p
deletions but did not reveal homozygous deletion or inacti-
vating mutations within expressed p73 sequences. How-
ever, alternative splice forms of p73 were detected and




(Eighteen neuroblastoma cell lines SJNB1 to SJNB20,
)excluding SJNB7 and SJNB19 , all derived at St. Jude
[ ]Children’s Research Hospital, were used in this study 21 .
Thirteen of the lines are characterized by MYCN amplifica-
tion, whereas SJNB1, SJNB3, SJNB9, SJNB12 and SJNB16
[ ] ( )have normal MYCN copy numbers 22 Table 1 . The cell
lines have been passaged 60 to 70 times.
Primary Tumors
Thirty-two primary tumor specimens were obtained from
( )the Pediatric Oncology Group Table 2 . All were classified
as having single-copy MYCN genes. Nineteen were diploid
and 12 were hyperdiploid. The samples were collected at
diagnosis, before the administration of chemotherapy or
radiation therapy. Specimens were immediately frozen in
liquid nitrogen and stored at y808C.
Patient Data
The 32 patients ranged in age from 4 days to 15.3 years,
with a median of 1.4 years. Twenty were older and 12 were
( )younger than 1 year 20 boys and 12 girls . Twenty-two
were classified as stage A, 4 as stage B, 3 as stage C, 2 as
( )stage D, and 1 as stage DS Table 2 .
P1 Clone of the p73 Gene for FISH Analysis
In order to isolate a genomic clone corresponding to the
p73 gene, we used PCR to amplify two p73 genomic
X(fragments with oligonucleotide sets from both the 5 ACCA-
)TGGACCAGATGAGCA; AGTGACCTCAAAGTGGTGGG
X(and 3 AGCAGGGCCACGACTACAGC; TTGGGGATGGT-
)GATGGTGTG portions of the gene. These oligonucleotides
were then used to screen a P1 library for the p73 gene
( )Genome Systems, Inc, St. Louis, MO, USA . One P1 clone
was obtained and introduced by electroporation into Electro-
( )Max DH10BTM cells Gibcol BRL, Life Technologies . The
transformed cells were then streaked onto kanamycin agar
plates. Single colonies were picked and incubated at 358C
overnight. The bacterial cells were collected, and DNA was
purified according to instructions from the company.
Table 1. p73 Copy Number and mRNA Sequence Analysis in Neuroblastoma Cell Lines.
Cell line MYCN p73 Chromosome 1 Nested Primer Sets
Status Copy No. Copy No. a b c D e f
SJNB1 Sc 2 4 N N N N N; sf1 N
SJNB3 Sc 2 2 N N N N N; sf1 N
SJNB9 Sc 2 4 LDP LDP N N N; sf1 N
SJNB12 Sc 3 4 N N LDP N LDP N
SJNB16 Sc 1 3 LDP LDP LDP N LDP LDP
SJNB2 Am 1 3 N N N N N; sf2 N
SJNB4 Am 1 2 LDP LDP LDP N LDP N
SJNB5 Am 1 2 N N N N N; sf1, sf2, sf3, sf4 N
SJNB6 Am 2 2 N N N N N; sf1, sf2, sf3, sf6 N
SJNB8 Am 2 3 629T-C N N N N; sf1, sf2, sf3, sf4 N
SJNB10 Am 2 4 N N N N N; sf1, sf2, sf3, sf6 N
SJNB11 Am 2 3 LDP LDP N N N; sf3 N
SJNB13 Am 3 4 LDP LDP LDP N LDP N
SJNB14 Am 2 3 N N N N N; sf1, sf2, sf3, sf4 N
SJNB15 Am 1 2 N N N N N; sf1, sf2, sf3, sf5 N
SJNB17 Am 2 3 N N N N N; sf2, sf3 N
SJNB18 Am 1 2 N N N N N; sf1, sf2, sf3, sf6 N
SJNB20 Am 2 4 N N N N N; sf1, sf2, sf3 N
Am, amplified; Sc, single copy; N, normal p73 sequence; LDP, lacking detectable product for sequence analysis; 629T-C, transition of T to C at
( ) ( ) ( ) ( )nucleotide 629; sf, p73 transcript splice form containing all of the 14 exons sf1 or lacking exon 13 sf2 , exon 11 sf3 , exons 11q 13 sf4 , exons
( ) ( )11q 12 sf5 , or 11q 12q 13 sf6 .
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Table 2. Clinical Features of Patients with Primary Neuroblastoma Lacking MYCN Amplification and Analysis of the p73 Gene in Tumor Specimens.
( )Patient No. Age yr Sex Tumor DI p73 Chromosome 1 Nested Primer Sets
Stage Copy No Copy No a b C D e e1 e2 f
1 1.9 F A 1.00 2 2 N N N N LDP N N N
2 1.3 M C 1.00 1 2 N N N N N; sf1 N N N
13 4.7 F C 1.00 NT NT N N N N LDP N N N
4 1.4 M A 1.00 2 3 N LDP LDP N LDP N N N
5 12.2 M A 1.00 NT NT N LDP LDP N LDP 135G–A N N
6 1.2 F A 1.00 2 2 N N N N N; sf1 N N N
7 4.2 M D 1.00 NT NT N N LPD N LDP N N N
8 5.8 M B 1.00 NT NT N N N N LDP N N N
9 2.8 M A 1.00 2 2 N N N N LDP N N N
10 15.3 F A 1.00 2 2 N N LDP N LDP N N N
11 2.0 F A 1.00 2 2 N N LDP N LDP N N N
12 Newborn M DS 1.00 1 2 N N LDP N LDP N N N
13 1.2 M B 1.00 2 2 N N N N LDP N N N
15 0.7 M C 1.00 2 2 N N N N LDP N N N
16 1.4 M D 1.18 2 2 N N N N N;sf1 N N N
17 Newborn M A 1.00 2 2 N N LDP N LDP N N N
18 6.2 F A 1.00 2 2 N N N N LDP N N N
19 3.0 F B 1.00 2 2 N N N N LDP N N N
20 0.9 M B 1.00 2 2 N N N N N; sf3 N N N
21 11.8 F A 1.00 2 2 N N N N LDP N N N
23 0.8 M A 1.46 NT NT N N N N LDP N N N
24 1.6 M A NT NT NT N N N N LDP N N N
25 1.5 F A 1.83 3 3 N N N N LDP N N N
26 0.7 F A 1.31 3 3 N N N N LDP N N N
27 Newborn M A 1.63 3 3 N N LDP N LDP N N N
28 0.9 M A 1.48 3 3 N N N N N; sf1 N N N
29 0.1 M A 1.18 3 3 N N LDP N LDP N N N
30 1.4 F A 1.25 4 4 N N LDP N LDP N N N
31 0.7 M A 1.69 NT NT N N N N LDP N N N
32 Newborn M A 1.45 NT NT N N N N LDP N N N
33 1.5 F A 1.20 3 3 N N LDP N LDP N N N
34 Newborn M A 1.30 2 2 N N N N LDP N N N
NT, not tested; N, normal p73 sequence; LDP, lacking detectable product for sequence analysis; 1358G-A, transition of G to A at nucleotide 1358; sf,
( ) ( )p73 transcript splice form containing all 14 exons sf1 or lacking exon 11 sf3 .
Fluorescence in Situ Hybridization
( )Colcemid 0.05 mg/mL was added to cells growing in
culture, and slides containing fixed metaphase cells were
[ ]prepared as previously described 23 . The primary tumor
cells were touched onto slides and then fixed with 75%
methanol and 25% glacial acetic acid. The hybridization and
fluorescence detection was performed under the reported
[ ]conditions 24 . DNA from the p73 P1 clone was labeled
with digoxigenin-11-dUTP or biotin-16-dUTP by nick transla-
( )tion. A control probe pUC1.77 , which is highly repeated in
the chromosome 1 pericentromeric heterochromatin, was
nick translated with biotin-16-dUTP and used in the hy-
bridization mixture to verify the copy number of chromo-
some 1. Signals were detected by incubating the slides with
fluorescein-conjugated sheep antidigoxigenin antibodies
( )Boehringer Mannheim and Texas red–conjugated avidin
Table 3. Primers Used in RT-PCR Analysis of the p73 Gene.
Primer pairs Sense Primers Antisense Primers Amplified Nucleotides
1 AGCGAGCTGCCCTCGGA AAGTGACCTCAAAGTGGTGGGG 78-501
2 GATTCCAGCATGGACGTCTT GATCTGGATGGGGCATGTCT 246-599
3 CCTCCAACACCGACTACCC GCCGATAGGAGTCCACCAGT 457-1281
4 CCGAAAAGCTGATGAGGAC GTGGCCATGGTTGTTGAG 1013-1484
5 CCGAAAAGCTGATGAGGAC TGGGGATGGTGATGGTGT 1013-1902
6 GAGATGAGCAGCAGCCACAG CTCCTGAGGCAGTTTTGGAC 1503-2110
A GTGGGGAAGATGGCCCAGT GACATGGTGTCGAAGGTGGAG 102-439
B CCTGGAGGGCATGACTACAT TGGCGATCTGGCAGTAGAG 269-579
C CCCACCACTTTGAGGTCACT TCAGCTCCAGGCTCTCTTTC 481-1242
D CTTGGTGCCGGTGTGAAG GCCGATAGGAGTCCACCAGT 1128-1281
E GCCTGGAGCTGATGGAGTT CTGTAGTCGTGGCCCTGCTT 1231-1774
F TGAAGATCCCCGAGCAGTA TTTGGACACACAGGAAGGA 1702-2097
e1 AGCCACTGGTGGACTCCTATC CTGTGGCTGCTGCTCATCT 1258-1522
e2 GAGATGAGCAGCAGCCACAG GTACTGCTCGGGGATCTTCA 1503-1721
Pairs 1-6 were used for RT-PCR, a-f for the nested PCR, and e1 and e2 for nested PCR to amplify primary tumor samples.
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( )Vector Laboratories , followed by signal amplification with
(fluorescein-conjugated rabbit antisheep antibodies Boeh-
)ringer Mannheim and biotinylated anti-avidin. Slides were
X ( )counterstained with 4 ,6-diamidino-2-phenylindole DAPI .
RT-PCR
Total RNA was extracted from neuroblastoma cell lines
(with RNA STAT-60e solution Tel-Test, Inc, Friendswood,
) [ ]TX according to a published procedure 25 . RT-PCR was
[ ]performed as previously described 26 . In brief, cDNAs
were reverse transcribed from 5 mg of total RNAs in a 20 mL
(mixture by use of a cDNA synthesis kit Boehringer
)Mannheim . Three microliters of the cDNA were amplified
by PCR by using the p73-specific oligonucleotide primers
( )Table 3 . Because p73 is expressed at low levels in normal
[ ]human tissues 16 , nested PCR was required for each of
the amplifications. The positions and sequences of the
oligonucleotide primers for the first RT-PCR and nested
PCR are shown in Figure 1 and Table 3. b-Actin–specific
oligonucleotides were used as a control for RNA integrity
[ ]27 .
Sequencing
PCR products were sequenced directly as described
[ ]previously with slight modifications 26 . The sequencing
primers were those used for nested PCR. If there were
several transcripts in one PCR product, then each band was
gel-purified, excised, and sequenced directly.
Results
p73 Gene Copy Number in Neuroblastoma Cell Lines
To determine whether the p73 gene is included in 1p
deletions in neuroblastoma cell lines, we performed FISH
analysis with a P1 genomic clone that contained the entire
p73 coding sequence. This probe was cohybridized with a
[ ]second probe, pUC1.77, 28 that recognizes repeated se-
quences from proximal 1q to determine the number of
chromosomes 1 in each cell line. Figure 2 shows examples
of the results obtained by interphase and metaphase FISH
analysis. Both p73 alleles were retained in cells from a
( )neuroblastoma cell line SJNB3 with 2 cytogenetically nor-
( )mal chromosomes 1 Figure 2A and B . One allele of p73 is
( )deleted in a neuroblastoma cell line SJNB5 with a cytoge-
( )netically visible 1p36 deletion Figure 2C and D . A te-
( )traploid cell line SJNB1 is characterized by retention of 2
p73 alleles and loss of p73 from the remaining chromo-
some 1 alleles with cytogenetically identical 1p deletions
( )Figure 2E and F .
When applied to a series of 18 neuroblastoma cell lines,
(FISH analysis yielded distinct patterns of p73 loss see
)Table 1 . The high frequency of chromosome 1 trisomy or
tetrasomy that accompanied 1p loss in these cell lines
underscores the need to determine the number of chromo-
somes 1 per cell with the pUC1.77 probe, as well as the
(number of p73 gene copies. In 4 of the cell lines SJNB4,
)SJNB5, SJNB15, and SJNB18 , the analysis indicated clas-
sical 1p deletion with complete loss of 1 p73 gene locus in
Figure 1. Structure of the p73 gene. The top row shows p73 domains predicted from amino acid sequence homology
[ ]between this protein and p53 16 . The bold lines in the second row indicate the location and the relative length of the
cDNA sequences amplified with the 6 pairs of primers used in the first round of PCR. p73 Exon boundaries are shown in
[ ]the third row 16 . The coding regions are indicated by solid boxes and the untranslated regions by open boxes. The fourth
( )row shows the cDNA segments a-f, e1, e2 used for direct sequence analysis, and after amplification with nested primer
pairs in a second round of PCR, with products of the first round of RT-PCR serving as templates. PCR products a-f were
analyzed by direct sequence techniques for mutations of the p73 coding sequence. Primers e1 and e2 were used for
analysis of mutations in exons 11-13 only in primary tumors.
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(Figure 2. FISH analysis of the p73 gene copy number in SJNB3, SJNB5, and SJNB1 cell lines. Interphase panels A, C,
) ( ) ( )and E and metaphase panels B, D, and F cells were hybridized with a p73 P1 clone green and the subcentromeric
( ) ( ) ( ) ( )control pUC1.77 probe red . A,B. SJNB3 cells possess 2 chromosomes 1 red and 2 p73 green signals. C,D. SJNB5
cells have 2 chromosomes 1 but retain only a single p73 allele. E,F. SJNB1 cells have tetrasomy of chromosome 1 but
only 2 copies of the p73 locus.
( )the context of 2 copies of chromosome 1 see Table 1 .
( )Similarly, 2 cell lines SJNB2 and SJNB16 had trisomy of
chromosome 1, but only 1 of these chromosomes 1 retained
( )the p73 gene on 1p see Table 1 . Thus, 6 of the 18 cell
lines were monosomic for the p73 locus on chromosome 1.
(Four additional cell lines SJNB1, SJNB9, SJNB10, and
)SJNB20 had tetrasomy of chromosome 1, but only 2 had
copies of the p73 locus. By cytogenetic analysis, each of
these lines had 2 apparently normal chromosomes 1, to-
gether with 2 chromosomes with morphologically identical
1p deletions, suggesting that the deletions occurred before
(reduplication, leading to tetraploidy. Six lines SJNB8,
)SJNB11, SJNB12, SJNB13, SJNB14, and SJNB17 had
trisomy or tetrasomy of chromosome 1 with deletion of 1
(allele of the p73 gene. Only 2 of the cell lines SJNB3,
)MYCN not amplified, and SJNB6, MYCN amplified had
disomy of chromosome 1 and lacked evidence of p73 gene
( )deletion see Table 1 .
Mutational Analysis of p73 mRNA in Neuroblastoma Cell
Lines
We used RT-PCR techniques to examine the sequence
of p73 mRNA expressed by neuroblastoma cell lines. Rela-
tively low levels of p73 mRNA expression by these cell lines
precluded amplification of the entire coding region. Thus, for
sequence analysis, we designed 6 pairs of primers for the
( )first round of the analysis see primer pairs 1 to 6, Figure 1 ,
in which we amplified portions of the mRNA, and 6 pairs of
(internal primers to perform nested PCR see primer pairs a
)to f, Figure 1 .
Detectable RT-PCR products were obtained after the first
round of PCR with RNA templates from subsets of the cell
( )lines. For example, with primer set 3 Figure 1 , RT-PCR
products were detected in RNAs of 7 of the 13 MYCN-
amplified neuroblastoma cell lines and 1 of the 5 single-copy
( )MYCN cell lines Figure 3A . After nested PCR analysis
with the internal primer set c, p73 cDNA fragments were
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Figure 3. RT-PCR analysis of p73 mRNA in neuroblastoma cell lines. Agarose gel electrophoresis of p73 cDNA fragments
( )amplified with different primer pairs. A. After the first round of RT-PCR amplification with primer set 3 see Figure 1 , PCR
( )products were detected in 8 of 18 cell lines, including one single-copy MYCN cell line SJNB1 and 7 MYCN-amplified lines
( )SJNB 5, 6, 8, 14, 17, 18, and 20 . B. After nested PCR with primer set c, products were detected in 14 of the cell lines, but
( )not in SJNB4, 12, 13, and 16. C. After a first round of RT-PCR with primer set 5 see Figure 1 and nested PCR with primer
set e, 6 different products were observed. The expected sizes of each of the bands are indicated on the right side of the
figure. D. Primers specific for b-actin mRNA were used to amplify products from each cell line, demonstrating RNA
integrity. The first and last lanes of each gel show the mobilities of markers consisting of a 100-bp ladder.
detected in 11 of the 13 MYCN-amplified cell lines and 3 of
(the 5 single-copy MYCN cell lines see Figure 3B and Table
)1 . Moreover, with a primer set that amplified mRNA se-
(quences from exons 9 and 10 see set d, Figure 1, and
)Table 1 and a control b-actin primer set for RNA integrity
( )see Figure 3D , products were detected in RNAs from each
of the tumor cell lines, indicating that p73 mRNA was
expressed. Presumably, the p73 mRNA levels were lower
in tumors in which products could only be detected with the
most effective primer set flanking exons 9 and 10.
We then analyzed each of the amplifiable RT-PCR prod-
ucts from the neuroblastoma cell lines by direct DNA se-
quence analysis. The sequence of each product was nor-
mal, except for a T™C substitution in codon 173 of the
RNA from SJNB8, which did not result in an alteration of the
( )amino acid sequence see Table 1 . However, with the
primer sets 5 and e, which amplify mRNA sequences be-
tween exons 10 and 14, 6 splice forms of p73 mRNA were
(detected in variable patterns among the 18 cell lines see
)Figure 3C . The exons contained in each of these splice
forms are illustrated in Figure 4, with a summary of the
results presented in Table 1. The sf3 isoform predominated
in most MYCN-amplified neuroblastoma cell lines. This find-
ing appears important, because others have shown that the
same isoform, referred to as g, has little activity in growth
suppression and efficiently forms heterocomplexes with
[ ] (other p73 isoforms 29 . In contrast to splice form sf1 Fig-
)ure 4A , the splice forms referred to as sf2, sf3, sf4, and sf6
alter the open reading frame, yielding shorter polypeptides
(of 499, 475, 555, and 404 amino acids, respectively Figure
)4A, B . The sf5 form results in an in-frame deletion of amino
acids encoded by exons 11 and 12, producing a 540 amino
acid polypeptide. Interestingly, each of the single-copy
MYCN neuroblastoma cell lines either lacked detectable
( )transcripts with primer sets 5 and e SJNB12 and SJNB16
or had only transcripts containing each of these exons
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Figure 4. Schematic representation of alternative splice forms of p73 mRNAs. A. Sf1, splice form 1, contains an intact p73
C terminus from exons 10 to 14; sf2 lacks exon 13; sf3 lacks exon 11; sf4 lacks exons 11 and 13; sf5 lacks exons 11 and
12; and sf6 lacks exons from 11 to 13. The arrows indicate the location of the translational termination codon in each splice
form. B. Predicted amino acid sequence encoded by p73 splice forms. Sf2, 3, 4, and 6 have out-frame deletions of exons
13, 11, 11q 13, or 11q 12q 13, which interrupt the open reading frame and yield products of 499, 475, 555, and 404
amino acids. Sf5 has an in-frame deletion of amino acids encoded by exons 11 and 12, producing a 540 amino acid
( )polypeptide. The underlined sequences indicate the shifted reading frame due to alternative splicing. The asterisk )
indicates the stop codon of each transcript.
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( )SJNB1, SJNB3 and SJNB9 , with no evidence of alterna-
( )tively spliced mRNAs see Figure 3C and Table 1 .
p73 Analysis in Primary Neuroblastomas With Single-Copy
MYCN
Because of the relative paucity of cell lines with
single-copy MYCN genes and initial reports suggesting that
[ ]p73 is an imprinted gene 16 , we extended our analysis to
include 32 primary neuroblastoma tumors lacking MYCN
( )amplification Table 2 . FISH analysis revealed that 2 diploid
( )tumors from cases 2 and 12 had monosomy of p73 and
disomy of chromosome 1, indicating deletion of one p73
( )allele. An additional case no. 4 had trisomy of chromo-
some 1 but only 2 copies of the p73 gene, also signifying
1p deletion, including the p73 locus. Thus, 3 of the 24
single-copy MYCN tumors evaluated by FISH showed dele-
tion of 1p, in agreement with the expected frequency of 1p
[ ]loss in this subgroup of neuroblastomas 12–15,30 .
p73 mRNA levels were low in primary neuroblastoma
( )samples, requiring nested PCR see Figure 1 for sequence
analysis of amplified segments. As shown in Table 2, we did
not identify nonsense or missense mutations in the p73
mRNA expressed by these tumors. The frequency of novel
C-terminal alternative splice forms identified in mRNAs from
neuroblastoma cell lines could not be analyzed in most
primary tumors, because the low levels of gene expression
precluded analysis with the informative primer sets 5 and e
( )see Table 2 . To analyze this portion of the p73 sequence
in RNA from primary tumors, primer set e was used in place
of set 5 to perform the first round of PCR reactions. Two
new primer sets, e1 and e2, were used to generate nested
PCR products from exons 10 through 14 in the primary
tumors. The sequence of these products matched the nor-
mal p73 sequence, except for a 1 nucleotide difference
identified in RNA from the primary tumor of case 5, which
(did not alter the predicted amino acid sequence see Table
)2 .
Discussion
Despite the location of p73 within a region that is frequently
deleted from 1 chromosomal allele in childhood neuroblas-
[ ]toma 16 , we did not identify inactivating mutations in p73
mRNAs expressed by 32 single-copy MYCN primary neu-
roblastomas and 18 neuroblastoma cell lines, including 13
with MYCN gene amplification. Thus, p73 does not appear
to be homozygously inactivated in this disease. By FISH
analysis, many of the neuroblastoma cell lines in our study
had MYCN gene amplification together with loss of one
allele of p73. The lack of detectable mutations in transcripts
expressed from the remaining allele is consistent with re-
sults of an earlier study suggesting that p73 does not
function as a classical suppressor in tumors with MYCN
[ ]gene amplification 16 .
Our original hypothesis, that p73 might represent the 1p
tumor suppressor thought to be preferentially inactivated in
tumors with single copies of MYCN per haploid genome
[ ] [ ]31 , was attractive for several reasons. Caron et al. 14
have documented preferential loss of the maternally derived
chromosome in this form of neuroblastoma by LOH analy-
sis, suggesting inactivation of the paternal allele of a sup-
pressor gene through gametic imprinting. When we initiated
this study, p73 was an attractive candidate for the putative
[ ]suppressor gene; indeed, the data of Kaghad et al 16 , had
demonstrated monoallelic expression of p73 in a small
number of normal persons heterozygous for an allelic poly-
morphism within the 5Xnoncoding exon of the gene. How-
ever, in a recently reported study, biallelic expression of p73
was detected in both primary neuroblastomas and a spec-
trum of normal tissues, indicating a lack of genomic imprint-
[ ]ing 32 . Our study did not specifically address the issue of
imprinting, but an RNA expression in each neuroblastoma
shown to have deletion of one allele of p73 argues against
imprinting as a mechanism of inactivation.
As reported here, only 3 of 26 MYCN single-copy pri-
mary tumors showed evidence of 1p loss by FISH analysis,
in accord with 1p LOH in a relatively low percentage of
[ ]tumors of this type 12–15,30 . The finding of a normal p73
mRNA sequence in the remaining tumors with sufficient
levels of expression for RT-PCR analysis would appear to
rule out biallelic inactivating lesions within the gene itself.
The lack of mutations in our study is significant because
single-point mutations in the region encoding the putative
DNA binding domain of p73, analogous to those observed
in p53 in human cancer cells, can block the antiproliferative
[ ]effects of p73 in in vitro assays 16,17 . Thus, if p73
operates as a tumor suppressor in either MYCN-amplified
or single-copy neuroblastoma, it likely operates through
alternative mechanisms, such as haploinsufficiency or pref-
erential expression of mRNA splice forms encoding domi-
nant-interfering proteins. A recently reported analysis sup-
ports the conclusion that p73 is unlikely to be a tumor
suppressor gene that is homozygously inactivated during
[ ]neuroblastoma development 32 .
Comparison of amino acid sequences between p73 and
p53 revealed striking homology, particularly within the
DNA-binding and oligomerization domains. Within the for-
mer, p73 shares 63% identity with p53, with conservation of
residues known to be critical for sequence-specific interac-
[ ]tions with DNA 16 . Functionally, p73 induces the expres-
sion of p53-responsive genes, such as p21Waf1/Cip1, and
[ ]inhibits cell growth by inducing apoptosis 16,17 . The car-
boxyl-terminal region of p73, however, lacks sequence simi-
larity to p53 but is homologous with recently identified
[ ]invertebrate p53 orthologs 16 , suggesting that these se-
quences have functional significance. In contrast to p53,
p73 was shown to be expressed in two forms, alpha and
beta, which have different coding sequences in this region.
The beta splice form, corresponding to sf2 in our study
( )Figure 4A and B , lacks exon 13. As a result, exon 14
sequences are placed in an alternative reading frame, lead-
ing to truncation of the protein by a stop codon after only 5
amino acids have been contributed to those encoded by
[ ]exon 12 16 .
We also identified several new splice forms by RT-PCR
( ) ( )Figure 4A and B , 1 of which lacked exon 11 sf3 and was
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a common form of p73 expressed by multiple cell lines with
MYCN gene amplification. Loss of exon 11 changed the
p73 reading frame, so that sequences from exons 12 and
13 encode a protein with a C terminus that differs from
either the alpha or beta form. This transcript was not identi-
fied in MYCN single-copy cell lines in the RT-PCR study, an
observation that may be biologically significant, although
studies of larger numbers of neuroblastoma tumors and cell
lines will be required to confirm this association. Other
splice forms of p73 were expressed at comparatively much
( ) ( )lower levels than the alpha sf1 , beta sf2 , and sf3 forms
( )Figure 3C and 4 .
Two of these splice forms were independently identified
[ ]by De Laurenzi et al. 29 , including sf3 and sf6, which they
referred to as g and d, respectively. The sf3, or g, isoform,
which lacks exon 11 and encodes a unique C terminus was
shown to form heterocomplexes with other p73 isoforms,
but not with p53. Furthermore, this isoform was the least
active of the 4 isoforms tested in terms of its ability to
transactivate expression of p21WAF1/CIP1 or to inhibit the
formation of cell colonies in clonogenic assays. The C-termi-
nal domain of p53 performs an important regulatory role in
that phosphorylation of amino acids in this region is required
to activate sequence-specific DNA binding by the central
[ ]region of the molecule 33–35 . The diminished growth
suppressive activity of the sf3 form of p73 suggests that its
C terminus also encodes a region with functional signifi-
cance. Thus, the predominance of the sf3 isoform in most
tumors with MYCN amplification suggests that it may se-
quester more active forms of p73 into inert complexes,
leading to a reduced capacity of this protein to interfere with
cell growth. Further analysis will be required to determine
whether differential expression of the sf3 isoform con-
tributes to oncogenesis through a dominant-negative mech-
anism.
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